Company intelligence / Profile preview
Stella Pharma
Osaka, Japanstella-pharma.co.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Stella Pharma has developed SPM‐011, a boron-containing small molecule drug used as part of boron neutron capture therapy (BNCT), an innovative radiotherapy for certain cancers. SPM‐011 has been approved in Japan for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. The company continues to develop BNCT applications for additional indications such as malignant glioma, meningioma, melanoma, and angiosarcoma[3].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeRadiopharmaceutical
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Stella Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stella Pharma.